Molebogeng (Lele) Rangaka, Clinical Associate Professor

Lele was appointed Clinical Associate Professor in 2019 – a position jointly held with the Institute of Global Health and the MRC Clinical Trials Unit at University College London (UCL). She is also an honorary Associate Professor at her alma mater, University of Cape Town in South Africa.

She is an ID Clinician Scientist with 20 years of experience. Her research areas span the epidemiology of poverty-related diseases, randomized assessments of public health technology, digital health innovation and implementation science. Her team conducts clinical trials of TB prevention across multimorbidities, people at risk, and world regions.

Lele sits on a number of international working groups including TB-LEAP, Collaboration for TB Vaccine Discovery (CTVD), the Cross-Network TB Vaccine Working Group (TB Vaccine WG),  Maternal and Child Working Group of the Union, the LTBI Task Force of the StopTB New Diagnostic Working Group, and is a member of the Lancet Digital Health International Advisory Board and UCL-TB Leadership.

Selected publications

Surey, J., Stagg, H. R., Yates, T. A., Lipman, M., White, P. J., Charlett, A., . . . Abubakar, I. (2021). An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study. BMC Infect Dis, 21 (1), 90. doi:10.1186/s12879-021-05766-9

Clarke, A. L., Sowemimo, T., Jones, A. S. K., Rangaka, M. X., & Horne, R. (2021). Evaluating patient education resources for supporting treatment decisions in latent tuberculosis infection. Health Education Journal. doi:10.1177/0017896921990066

Farao, J., Malila, B., Conrad, N., Mutsvangwa, T., Rangaka, M. X., & Douglas, T. S. (2020). A user-centred design framework for mHealth. PloS one, 15 (8), e0237910. doi:10.1371/journal.pone.0237910

Gupta, R. K., Turner, C. T., Venturini, C., Esmail, H., Rangaka, M. X., Copas, A., . . . Noursadeghi, M. (2020). Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. Lancet Respir Med. doi:10.1016/S2213-2600(19)30282-6

Gupta, R. K., Calderwood, C. J., Yavlinsky, A., Krutikov, M., Quartagno, M., Aichelburg, M. C., . . . Abubakar, I. (2020). Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nature Medicine, 26, 1941-1949. doi:10.1038/s41591-020-1076-0

Ross, J. M., Badje, A., Rangaka, M., Walker, A., Shapiro, A., Thomas, K., . . . Barnabas, R. (2020). Isoniazid Preventive Therapy Added to ART to Prevent TB: An Individual Participant Data Meta-Analysis. The Lancet HIV.

Research Interests

• TB, HIV, COVID, multimorbidity
• TB prevention: TB preventive treatment, TB Vaccines, Host-directed therapies
• Digital Health
• Trials Methodology
• Cluster Randomised Trials

Research Areas

HIV

Tuberculosis

COVID

NCD

Methodology